STOCK TITAN

SAVA Form 3 shows director with zero beneficial ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Cassava Sciences (SAVA) filed a Form 3 initial statement of beneficial ownership. The reporting person is identified as a Director and reported no securities beneficially owned. The date of event is 10/21/2025.

The filing includes Exhibit 24 – Power of Attorney and was filed by one reporting person. This is an administrative disclosure and does not reflect a transaction.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Bir Dawn Carter

(Last) (First) (Middle)
6801 N CAPITAL OF TEXAS HWY, BLDG 1
SUITE 300

(Street)
AUSTIN TX 78731

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/21/2025
3. Issuer Name and Ticker or Trading Symbol
CASSAVA SCIENCES INC [ SAVA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 – Power of Attorney
No securities are beneficially owned.
/s/ Eric J. Schoen by Power of Attorney 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cassava Sciences (SAVA) report in this Form 3?

A Director filed an initial statement of beneficial ownership and reported no securities beneficially owned.

What is the event date on the SAVA Form 3?

The Date of Event is 10/21/2025.

What is the reporting person’s relationship to Cassava Sciences (SAVA)?

The reporting person is a Director.

Does the Form 3 show any SAVA shares or derivatives owned?

No. The remarks state: No securities are beneficially owned.

Was a Power of Attorney included with the filing?

Yes. The remarks reference Exhibit 24 – Power of Attorney.

Who signed the SAVA Form 3?

The form was signed /s/ Eric J. Schoen by Power of Attorney on 10/22/2025.
Cassava Sciences

NASDAQ:SAVA

SAVA Rankings

SAVA Latest News

SAVA Latest SEC Filings

SAVA Stock Data

98.55M
42.11M
12.79%
25.22%
12.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN